CA2236598A1 - Treatment of cardiomyopathy by removal of autoantibodies - Google Patents

Treatment of cardiomyopathy by removal of autoantibodies

Info

Publication number
CA2236598A1
CA2236598A1 CA002236598A CA2236598A CA2236598A1 CA 2236598 A1 CA2236598 A1 CA 2236598A1 CA 002236598 A CA002236598 A CA 002236598A CA 2236598 A CA2236598 A CA 2236598A CA 2236598 A1 CA2236598 A1 CA 2236598A1
Authority
CA
Canada
Prior art keywords
patient
column
treatment
immunoapheresis
pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002236598A
Other languages
French (fr)
Other versions
CA2236598C (en
Inventor
Stephan Felix
Petra Reinke
Stefan Brehme
Gert Baumann
Robert Koll
Jutta Muller-Derlich
Reiner Spaethe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edwards Lifesciences Corp
Original Assignee
Baxter International Inc.
Stephan Felix
Petra Reinke
Stefan Brehme
Gert Baumann
Robert Koll
Jutta Muller-Derlich
Reiner Spaethe
Edwards Lifesciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc., Stephan Felix, Petra Reinke, Stefan Brehme, Gert Baumann, Robert Koll, Jutta Muller-Derlich, Reiner Spaethe, Edwards Lifesciences Corporation filed Critical Baxter International Inc.
Priority claimed from PCT/US1996/018457 external-priority patent/WO1997017980A1/en
Publication of CA2236598A1 publication Critical patent/CA2236598A1/en
Application granted granted Critical
Publication of CA2236598C publication Critical patent/CA2236598C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)

Abstract

Immunoapheresis treatment for cardiomyopathy comprises passing the patient's plasma over a column having coupled thereto a specific ligand for human immunoglobulin, thereby removing a significant portion of the immunoglobulin from the patient's plasma, and then reinfusing the plasma to the patient. The invention is the use of a specific ligand for human immunoglobulin in the manufacture of a column having the ligand coupled thereto, the column being useful for immunoapheresis treatment of a patient with cardiomyopathy.
The specific ligand binds, and thereby removes, human autoantibodies which are harmful to cardiac tissue such as antibodies against .beta.1-adrenergic receptors, ADP-ATP carriers, .alpha. and .beta. myosin heavy chains, and adenine nucleotide translocators. Immunoapheresis treatment using the column results in improvement of hemodynamic parameters such as mean arterial pressure, mean pulmonary pressure, pulmonary capillary wedge pressure, right atrial pressure, cardiac output, cardiac index, stroke volume index, and systemic vascular resistance.
CA002236598A 1995-11-15 1996-11-15 Treatment of cardiomyopathy by removal of autoantibodies Expired - Lifetime CA2236598C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55926295A 1995-11-15 1995-11-15
US08/559,262 1995-11-15
PCT/US1996/018457 WO1997017980A1 (en) 1995-11-15 1996-11-15 Treatment of cardiomyopathy by removal of autoantibodies

Publications (2)

Publication Number Publication Date
CA2236598A1 true CA2236598A1 (en) 1997-05-22
CA2236598C CA2236598C (en) 2006-09-12

Family

ID=36999314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002236598A Expired - Lifetime CA2236598C (en) 1995-11-15 1996-11-15 Treatment of cardiomyopathy by removal of autoantibodies

Country Status (1)

Country Link
CA (1) CA2236598C (en)

Also Published As

Publication number Publication date
CA2236598C (en) 2006-09-12

Similar Documents

Publication Publication Date Title
ATE266415T1 (en) TREATMENT OF DILATED CARDIOMYOPATHY BY REMOVAL OF AUTOANTIBODIES
CA2235372A1 (en) Method for treating ischemic tissue
FI963759A (en) Metallocene compounds, process for their preparation and their use in catalysts for the polymerization of olefins
CA2107556A1 (en) Increasing blood-brain barrier permeability with permeabilizer peptides
EP0890642A3 (en) Retrovirus of the HIV-group and its application
FR2703693B1 (en) Rapid method of determining a DNA sequence and application to sequencing and diagnosis.
WO1997017446A3 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
EP0871726A4 (en) Multispecific chimeric receptors
DE69220946D1 (en) USE OF NUCLEIC ACID ANALOGS IN DIAGNOSTIC AND ANALYTICAL METHODS
WO2001012659A3 (en) Human dna sequences
AU4090697A (en) Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one
CA2025597A1 (en) Vaccine against lyme disease
EP0911390A3 (en) Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease
ATE419275T1 (en) ANTIBODIES AGAINST VLA-4
EP1082433A4 (en) Interleukins-21 and 22
NO960123L (en) Fluorescent latex containing two fluorochromes, process for its preparation and use thereof
WO1999008109A3 (en) Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
EE200000627A (en) Human BMP-7 Promoter DNA, Production Method, Expression Vector, and Method for Investigation of Bone and Kidney Disease Substance
CA2236598A1 (en) Treatment of cardiomyopathy by removal of autoantibodies
AU6572596A (en) Method of recovering immunoglobulin from fractions produced during fractionation of human blood plasma
ITBO930059A0 (en) PROCEDURE TO OBTAIN TISSUE REGENERATION IN PERIODENTAL DENTISTRY THERAPY.
WO1998018822A3 (en) Novel human lim proteins
WO2001041813A3 (en) Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
WO2001032693A3 (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
WO1998018942A3 (en) Novel human rab proteins

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20161115